Animal Models of Diabetic Retinopathy
Tóm tắt
Tài liệu tham khảo
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet [Internet]. 2010;376(9735):124–36. Available from: http://www.sciencedirect.com/science/article/pii/S0140673609621243 .
•• Cho H, Sobrin L. Genetics of diabetic retinopathy. Curr Diab Rep [Internet]. 2014;14(8):515. doi:10.1007/s11892-014-0515-z. This is an important reference because it provides insight on how genetics plays a role in diabetic retinopathy. Understanding this will give more information on future development of therapies for treatment of this area.
Karalliedde J, Gnudi L. Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial Transplant [Internet]. 2016;31(2):206–13. doi:10.1093/ndt/gfu405.
Thayer TC, Wilson BS, Mathews CE. Use of NOD mice to understand human type 1 diabetes. Endocrinol Metab Clin North Am [Internet]. 2010;39(3):541–61. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2925291/.
• Pearson JA, Wong FS, Wen L. The importance of the non obese diabetic (NOD) mouse model in autoimmune diabetes. J Autoimmun [Internet]. 2016;66:76–88. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765310/. The article discusses the use of a nonobese diabetic animal model. The use of this model has helped uncover the significance of environmental factors in the DR disease. It is also an important model to understanding autoimmune diseases in diabetes and identify the role of the immune system in disease progression.
Dixon KC, King AJ, Malinin T. Protein in dying β-cells of the pancreatic islets. Q J Exp Physiol Cogn Med Sci [Internet]. 1960;45(2):202–12. doi:10.1113/expphysiol.1960.sp001458.
Cooperstein S, Watkins D. Alloxan. In The islets of Langerhans. Press A, editor. New York; 1981. 388–411 p.
Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963;29:91–8.
Jonasson O, Jones CW, Bauman A, John E, Manaligod J, Tso MO, et al. Ann Surg Lippincott, Williams, and Wilkins. 1985;201(1):27.
• Weerasekera LY, Balmer LA, Ram R, Morahan G. Characterization of retinal vascular and neural damage in a novel model of diabetic retinopathy. A novel mouse model of DR. Invest Ophthalmol Vis Sci Assoc Res Vis Ophthalmol. 2015;56(6):3721–30. Using the recently developed “Collaborative Cross” mouse resource, this study showed for the first time that alloxan-induced DR in mice could manifest in cellular lesions. The creation of mouse strains with high genetic diversity allows for development of new DR models that recapitulate more phenotypes of human disease than were previously possible.
White FR. Streptozotocin. Cancer Chemother Rep. 1963;30:49–53.
Drago F, La Manna C, Emmi I, Marino A. Effects of sulfinpyrazone on retinal damage induced by experimental diabetes mellitus in rabbits. Pharmacol Res Elsevier. 1998;38(2):97–100.
Acharya NK, Qi X, Goldwaser EL, Godsey GA, Wu H, Kosciuk MC, et al.. Retinal pathology is associated with increased blood-retina barrier permeability in a diabetic and hypercholesterolaemic pig model: beneficial effects of the LpPLA2 inhibitor darapladib. Diabetes Vasc Dis Res [Internet]. 2017;1479164116683149. Available from: http://journals.sagepub.com/doi/10.1177/1479164116683149%0A http://www.ncbi.nlm.nih.gov/pubmed/28301218
Barber AJ, Antonetti DA, Kern TS, Reiter CEN, Soans RS, Krady JK, et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci [Internet]. 2005;46(6):2210–8. doi:10.1167/iovs.04-1340.
Han Z, Guo J, Conley SM, Naash MI. Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy. Invest Ophthalmol Vis Sci [Internet] Assoc Res Vis Ophthalmol. 2013;54(1):574–84. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558298/.
Gastinger MJ, Singh RSJ, Barber AJ. Loss of cholinergic and dopaminergic amacrine cells in streptozotocin-diabetic rat and Ins2Akita-diabetic mouse retinas. Invest Ophthalmol Vis Sci [Internet]. 2006;47(7):3143–50. doi:10.1167/iovs.05-1376.
Gastinger MJ, Kunselman AR, Conboy EE, Bronson SK, Barber AJ. Dendrite remodeling and other abnormalities in the retinal ganglion cells of Ins2Akita diabetic mice. Invest Ophthalmol Vis Sci [Internet]. 2008;49(6):2635–42. doi:10.1167/iovs.07-0683.
Leiter EH. The NOD mouse: a model for analyzing the interplay between heredity and environment in development of autoimmune disease. ILAR J [Internet]. 1993 Jan 1;35(1):4–14. doi:10.1093/ilar.35.1.4.
Baxter AG, Cooke A. The genetics of the NOD mouse. Diabetes Metab Rev [Internet] Wiley. 1995;11(4):315–35. doi:10.1002/dmr.5610110403.
Lee S, Harris NR. Losartan and ozagrel reverse retinal arteriolar constriction in non-obese diabetic mice. Microcirculation [Internet]. 2008;15(5):379–87. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527598/.
Seino S. A novel rat model of type 2 diabetes: the Zucker fatty diabetes mellitus ZFDM rat. Exp Diabetes Res Hindawi Publishing Corporation. 2013;2013
Watanabe TK, Suzuki M, Yamasaki Y, Okuno S, Hishigaki H, Ono T, et al. Mutated G-protein-coupled receptor GPR10 is responsible for the hyperphagia/dyslipidaemia/obesity locus of Dmo1 in the OLETF Rat. Clin Exp Pharmacol Physiol Wiley Online Library. 2005;32(5–6):355–66.
Hornum L, Rømer J, Markholst H. The diabetes-prone BB rat carries a frameshift mutation in Ian4, a positional candidate of Iddm1. Diabetes Am Diabetes Assoc. 2002;51(6):1972–9.